Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accounts Payables (2021 - 2025)

Historic Accounts Payables for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $1.1 million.

  • InMed Pharmaceuticals' Accounts Payables rose 1172.38% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 1172.38%. This contributed to the annual value of $1.4 million for FY2025, which is 1509.83% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Accounts Payables stood at $1.1 million, which was up 1172.38% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Accounts Payables peaked at $3.4 million during Q4 2021, and registered a low of $1.0 million during Q3 2024.
  • In the last 5 years, InMed Pharmaceuticals' Accounts Payables had a median value of $1.6 million in 2023 and averaged $1.8 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Accounts Payables surged by 2314.41% in 2022, and later crashed by 5570.84% in 2023.
  • InMed Pharmaceuticals' Accounts Payables (Quarter) stood at $3.4 million in 2021, then plummeted by 41.33% to $2.0 million in 2022, then plummeted by 34.65% to $1.3 million in 2023, then rose by 6.49% to $1.4 million in 2024, then decreased by 17.58% to $1.1 million in 2025.
  • Its Accounts Payables was $1.1 million in Q3 2025, compared to $1.4 million in Q2 2025 and $1.4 million in Q1 2025.